GENE ONLINE|News &
Opinion
Blog

2021-11-08| In-DepthSpecial

New Research Marks a Paradigm Shift in Countering Alzheimer’s Disease

by Arvind C. Shekhar
Share To
Alzheimer's disease (AD) is the most common neurodegenerative disease, with more than 40 million cases reported worldwide. AD is characterized by the aggregation of both the β-Amyloid (Aβ) proteins into plaques and of the tau proteins into neurofibrillary tangles (NFTs) known collectively as aggregates which cause brain cells to die and the brain to shrink.

It had been believed that aggregation begins in a single location, spreading from one brain region to the next. A key limiting factor in disease progression is at what rate these processes occur and how important the local replication of seeds and their spread over longer length scales between brain regions, are for determining the time scale of human disease. 

Recent results, reported in the journal Science Advances, have opened up new avenues of understanding the progress of Alzheimer's and other neurodegenerative diseases and possibly new ways that future treatments might be developed.

The researchers developed a mathematical model to simulate the progression of the disease and applied it to five different imaging datasets. By combining the five different datasets, the researchers observed that the mechanism controlling the rate of progression in Alzheimer's disease is the replication of aggregates in individual regions of the brain and not the spread of aggregates from one region to another.

GO Prime with only $1.49 now

LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top